Mirimus Named A Winner in $6M XPRIZE Rapid COVID Testing Competition Mirimus one of five finalists from the main track eligible to receive $1 million Pioneering SalivaClear pooled testing platform is designed to provide frequent, high-quality, low-cost detection of SARS-CoV-2, the virus that causes COVID-19 News provided by Share this article Share this article NEW YORK, March 16, 2021 /PRNewswire/ -- Mirimus, Inc., a leader in conducting high-volume, high-quality PCR testing, today announced it has been named as one of five winners in XPRIZE Rapid COVID Testing for its pioneering SalivaClear ™ COVID-19 pooled saliva testing platform. The SalivaClear platform is composed of three key elements – saliva-based sampling, pooled testing and gold-standard PCR molecular diagnostics – that, when combined, enable frequent, high-quality, high-throughput, low-cost detection of SARS-CoV-2, the virus that causes COVID-19.